94 completed. 94 Phase 1, 31 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 94 | Completed 94 |
| Phase 2 | 31 | Completed 31 |
Follow Primary Myelofibrosis: new trials by email Literature Review of Primary Myelofibrosis trials Research Report on Primary Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects TQ05105 - Myelofibrosis | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 32 | 2024-10-12 | 2025-08-24 |
| TP-3654 Food Effect Study TP-3654 - Myelofibroses | Phase 1 | Completed | Sumitomo Pharma America, Inc. | 24 | 2024-03-04 | 2026-03-25 |
| Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions Jaktinib Hydrochloride Tablets - Myelofibrosis | Phase 1 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 52 | 2023-11-29 | 2024-01-11 |
| A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets TQ05105 tablets, Itraconazole capsule, Rifampicin Capsule - Myelofibrosis | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 40 | 2023-09-21 | 2025-12-12 |
| To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects TQ05105 Tablets - Myelofibrosis | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 16 | 2021-07-19 | 2023-08-08 |
| Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis PXS-5505 - Myelofibrosis, Primary Myelofibrosis (PMF) | Phase 1 / Phase 2 | Completed | Syntara | 43 | 2021-02-18 | 2026-08-04 |
| MPN-RC 118 AVID200 in Myelofibrosis AVID200 - Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | Phase 1 | Completed | John Mascarenhas | 21 | 2019-02-15 | 2023-02-10 |
| A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies PRT543 - Relapsed/Refractory Advanced Solid Tumors, Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 1 | Completed | Prelude Therapeutics Incorporated | 232 | 2019-02-11 | 2023-03-28 |
| CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms CALRLong36 peptide - Myeloproliferative Neoplasm, Unclassifiable, Essential Thrombocythemia | Phase 1 | Completed | Inge Marie Svane | 10 | 2018-06-20 | 2023-07-13 |
| Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) Bomedemstat - Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF) | Phase 1 / Phase 2 | Completed | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 90 | 2017-07-18 | 2024-01-10 |
| Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT Fludarabine, Busulfan, Cyclophosphamide - Non-Hodgkin's Lymphoma, Acute Leukemia in Remission | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 32 | 2017-01-31 | 2021-09-16 |
| Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis Allogeneic Hematopoietic Stem Cell Transplantation, Fludarabine, Fludarabine Phosphate - Primary Myelofibrosis, Secondary Myelofibrosis | Phase 1 | Completed | City of Hope Medical Center | 18 | 2016-11-13 | 2023-12-12 |
| Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Fludarabine, Busulfan, Rabbit ATG - Leukemia, Lymphoid, Leukemia, Myeloid | Phase 1 | Completed | Dartmouth-Hitchcock Medical Center | 20 | 2016-09-06 | 2023-10-18 |
| Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg Ruxolotinib, peg-IFN alpha -2a - Myelofibrosis | Phase 1 / Phase 2 | Completed | French Innovative Leukemia Organisation | 37 | 2016-03-01 | 2022-07-27 |
| Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) Tagraxofusp Injection - Myelofibrosis, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Completed | Stemline Therapeutics, Inc. | 82 | 2016-02-10 | 2025-01-06 |
| A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF) Placebo, Ruxolitinib, Vismodegib - Myelofibrosis | Phase 1 | Completed | Hoffmann-La Roche | 10 | 2016-01-25 | 2018-05-11 |
| PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis Allogeneic hematopoietic stem cell transplantation, Busulfan, Fludarabine monophosphate - Primary Myelofibrosis, Myeloproliferative Disorders | Phase 1 / Phase 2 | Completed | St. Petersburg State Pavlov Medical University | 20 | 2016-01-01 | 2019-04-04 |
| URMC Related Haplo-identical Donor BMT Total Body Irradiation 1200 cGy, Fludarabine, Pre-Stem Cell Infusion Cyclophosphamide - Hematological Disease, Immune Deficiencies | Phase 1 | Completed | University of Rochester | 74 | 2015-10-01 | 2021-11-03 |
| TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea TGR-1202, ruxolitinib - Myelofibrosis, Polycythemia Vera | Phase 1 | Completed | Vanderbilt-Ingram Cancer Center | 60 | 2015-07-01 | 2026-05-19 |
| Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis PIM447, Ruxolitinib, LEE011 - Myelofibrosis | Phase 1 | Completed | Novartis Pharmaceuticals | 15 | 2015-05-21 | 2022-02-09 |
Showing 20 of 94. Sign in to see all of them.
Leukemia, Myeloid, Acute (47) · Myeloproliferative Disorders (46) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (43) · Leukemia, Lymphocytic, Chronic, B-Cell (39) · Leukemia, Myelomonocytic, Chronic (39) · Myelodysplastic Syndromes (39) · Thrombocythemia, Essential (37) · Polycythemia Vera (36) · Leukemia (35) · Multiple Myeloma (35) · Hodgkin Disease (32) · Lymphoma, Mantle-Cell (32) · Lymphoma, Non-Hodgkin (32) · Burkitt Lymphoma (31)
Hemic and Lymphatic Diseases (94) · Bone Marrow Diseases (91) · Hematologic Diseases (90) · Neoplasms (63) · Neoplasms by Histologic Type (57) · Leukemia, Myeloid (54) · Pathologic Processes (54) · Pathological Conditions, Signs and Symptoms (54) · Disease Attributes (53) · Chronic Disease (52) · Immune System Diseases (51) · Hemorrhagic Disorders (50) · Immunoproliferative Disorders (50) · Lymphatic Diseases (50) · Lymphoproliferative Disorders (49)
ruxolitinib (13) · fludarabine phosphate (12) · Busulfan (10) · Cyclophosphamide (10) · Peripheral Blood Stem Cell Transplantation (10) · Tacrolimus (9) · Filgrastim (8) · Methotrexate (7) · fludarabine (7) · Antilymphocyte Serum (5) · Etoposide (5) · Whole-Body Irradiation (5) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (4) · Cyclosporine (4) · Mycophenolic Acid (4)
National Cancer Institute (NCI) (7) · Case Comprehensive Cancer Center (3) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (3) · Fred Hutchinson Cancer Center (3) · M.D. Anderson Cancer Center (3) · Novartis Pharmaceuticals (3) · Asan Medical Center (2) · CTI BioPharma (2) · California Cancer Consortium (2) · City of Hope Medical Center (2) · Eli Lilly and Company (2) · Incyte Corporation (2) · Indiana University (2) · John Mascarenhas (2) · Mayo Clinic (2)
United States (76) · Germany (11) · Canada (9) · France (8) · Italy (8) · United Kingdom (7) · Australia (6) · China (5) · Netherlands (4) · South Korea (4) · Belgium (2) · Denmark (2) · Ireland (2) · Moldova (2) · Poland (2)
Ayalew Tefferi, MD (5) · John Mascarenhas, MD (2) · Kyoo H. Lee, MD (2) · Martha Wadleigh, MD (2) · Richard K. Burt, MD (2) · Ronald Hoffman, MD (2) · Ruben Mesa, MD (2) · Alex Shalaurov, MD, PhD (1) · Andrew Roberts, M.D. (1) · Andrew Roberts, MD (1) · Animesh Pardanani, MD (1) · Ann Mohrbacher, MD (1) · Aref Al-Kali (1) · Becker Hewes, MD (1)
PMID 15570084, PMID 17562873, PMID 20843246, PMID 21742281, PMID 22259028, PMID 22547163, PMID 22718840, PMID 23993427, PMID 24002496, PMID 24474568, PMID 24530972, PMID 25762180, PMID 26210442, PMID 26853648, PMID 27479177, PMID 27634203, PMID 27931243, PMID 28934680, PMID 29515114, PMID 29544547, PMID 30249277, PMID 30562587, PMID 31778911, PMID 32325461, PMID 32396615, PMID 32634234, PMID 33635333, PMID 33718228, PMID 34581764, PMID 36105914, PMID 36881782, PMID 37530627, PMID 38118249, PMID 38259250, PMID 39924599, PMID 40241543, PMID 40643151, PMID 40919483, PMID 41146971, PMID 41758981, PMID 42013378, PMID 42054549
2018 (3), P30CA006973 (2), P30CA015083 (2), U01CA062491 (2), 2014 (1), 2015 (1), P01CA015396 (1), P01CA108671 (1), P30CA014599 (1), P30CA016058 (1), P30CA016086 (1), P30CA016087 (1), P30CA023074 (1), P30CA033572 (1), P30CA043703 (1)